Navigation Links
Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs
Date:7/27/2014

Columbus, OH (PRWEB) July 27, 2014

Wright & Schulte LLC has learned that the state of Louisiana has filed a GranuFlo lawsuit against Fresenius Medical Care North America and its nearly 100 clinics in Louisiana over the recalled dialysis drugs GranuFlo and NaturaLyte. The complaint purports that Fresenius defrauded the state’s Medicaid program by not disclosing the heart attack risks associated with the two drugs. Louisiana’s dialysis medication lawsuit contends that Fresenius notified its own clinics, practitioners and physicians about the problems with the dialysis concentrates but did not notify the approximately 1,500 non-Fresenius clinics, practitioners and physicians of the dangers. The Louisiana Attorney General’s Office filed the dialysis treatment lawsuit on June 26, 2014, in the 19th Judicial District Court, Parish of East Baton Rouge. (The State of Louisiana vs. Fresenius Medical Care, Case No. 631586).

In March 2012, Fresenius Medial made public its concerns about GranuFlo and NaturaLyte potentially causing cardiac arrest in dialysis patients and issued a recall of the products. The FDA classified the recall as Class 1, the most serious type of recall issued by the federal agency.

The attorneys at Wright & Schutle continue to investigate GranuFlo lawsuit claims and offer free legal consultations to those who believe they have suffered dialysis side-effects such as sepsis, bacteremia, cardiac events and even death

Louisiana’s dialysis lawsuit further contends that Fresenius violated state law that prohibits unfair and deceptive practices because the company misrepresented GranuFlo and NaturaLyte as safe to administer to dialysis patients and continued to submit claims to Medicaid for reimbursement for its services. Louisiana’s GranuFlo lawsuit seeks civil penalties of $5,000 per violation under the state’s Unfair Trade Practices and Consumer Protection Law. The Nephrology News & Issues reported that Louisiana appears to be the first state to file a dialysis lawsuit against Fresenius, which also faces complaints by individual patients across the country.
[nephrologynews.com/articles/110304-louisiana-sues-fresenius-to-reclaim-payment-over-granuflo-use, July 1, 2014]

In March 2012, Fresenius made public its concerns about GranuFlo and NaturaLyte potentially causing cardiac arrest in dialysis patients and issued a recall of the products. The FDA classified the recall as Class 1, the most serious type of recall issued by the federal agency.

The U.S.Food & Drug Administration (FDA) describes GranuFlo and NaturaLyte as dialysis concentrates used to treat acute and chronic renal failure by neutralizing acid in the blood. Improper use of the products can cause dialysis patients to have metabolic alkalosis, a high serum bicarbonate level that can lead to heart attack, stroke, cardiac arrest, dangerously low blood pressure or sudden cardiac death. [fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305630.htm, June 27, 2012]

The New York Times reported that Fresenius only made the information public after an internal company memo was anonymously sent to the FDA about the products. Fresenius’ November 2011 memo warned doctors at its dialysis clinics that improper use of the two products appeared to be a factor in patients dying suddenly from cardiac arrest. The memo mentioned that a company study found that 941 patients experienced cardiac arrest in Fresenius clinics in 2010. The memo was not sent to other clinics that Fresenius did not own. After the FDA questioned Fresenius about the memo, the company warned other non-Fresenius clinics about concerns over the two products.
[nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0, June 14, 2012]

Fresenius recently issued a new recall of more NaturaLyte products. According to the FDA, Fresenius recalled 49 lots of NaturaLyte liquid bicarbonate concentrate on April 10, 2014, due to concerns over the product developing higher than expected bacteria levels during its shelf life. Fresenius expanded the recall in May to include nine additional lots. Just as it did in 2012, the FDA classified the recall as Class 1, the most serious type of recall. The FDA noted in its safety alert that the agency had received one report of a patient’s death and two reports of injury that may be related to the recalled NaturaLyte product. The FDA also warned that the product may cause serious health consequences, including sepsis, bacteremia, and death.
[fda.gov/MedicalDevices/Safety/ListofRecalls/ucm399124.htm, June 5, 2014]

Court documents show that GranuFlo litigation is currently underway in the U.S. District Court, District of Massachusetts. The court’s Master Case List shows 1,863 GranuFlo lawsuits have been filed in the federal litigation as of June 16, 2014. Judge Douglas P. Woodlock, who is presiding over the litigation, has scheduled the first bellwether trial for a GranuFlo dialysis lawsuit will take placen in January of 2016, with a second bellwether trial scheduled for February of 2016. The complaints were filed on behalf of dialysis patients who allege that they suffered heart attacks, strokes, cardiac arrest or sudden cardiac death as a result of being given the recalled GranuFlo or NaturaLyte concentrates during dialysis. (In Re: Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428) The lawsuits also question why Fresenius withheld information from clinics that were not in its network of clinics about the dangers of using GranuFlo and NaturaLyte products during dialysis.[jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-June-16-2014.pdf, June 16, 2014]

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free GranuFlo lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Read the full story at http://www.prweb.com/releases/2014/07/prweb12048671.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Louisiana Recognizes Dangers of Synthetic Marijuana
2. Louisiana Tech University professor, researcher receives prestigious Humboldt Prize
3. Acadian Ambulance and Air Med Honored by Louisiana State Police
4. Painting by Louisiana Artist Accepted into MDA Art Collection
5. SC&H Capital Advises LSU Hospitals in Privatization Deal in Louisiana
6. NuvaRing Lawsuit Filed by Alonso Krangle Alleges That Use of NuvaRing Caused a Louisiana Woman to Develop a Life-Threatening Blood Clot Disorder
7. World-Renowned Autism Expert Dr. Doreen Granpeesheh Presents Keynote Address at CARD Louisiana Autism Conference, August 24th in Baton Rouge
8. North American Seminars Receives PT Continuing Education Course Approval in Louisiana for The Lumbopelvic Region Presented September 21-22, 2013 at East Jefferson General
9. Evamor Products, LLC Partners with Crescent Crown Distributing Co., Inc. for Louisiana Market Growth
10. NuvaRing Lawsuit Filed by Alonso Krangle on Behalf of a Louisiana Woman Who Developed Pulmonary Embolism Allegedly Due to NuvaRing Use
11. Well Community Project Grants $180,000 to Community Organizations in Mississippi, Michigan, and Louisiana to Promote Wellness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology: